2nd Quarter - Report — DALRYMPLE & ASSOCIATES, LLC for SANOFI PASTEUR (2014)

Firm

DALRYMPLE & ASSOCIATES, LLC

Client

SANOFI PASTEUR

Income

$46,000

Expenses

—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
2nd Quarter - Report	Jul 21, 2014	$61,000	Replaced
2nd Quarter - Report (this page)	Oct 9, 2014	$46,000	Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Childhood, adult and biodefense vaccine issues

Foreign entity interest: 100% Sanofi Pasteur Worldwide, 2 Avenue Point, F-69367, Lyon, France

Lobbyist	Covered position, as disclosed
DONALD DALRYMPLE New	Principal

Contacted: Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Budget/Appropriations BUD

Funding and appropriations for adult, childhood and biodefense vaccines and other medical countermeasures

Foreign entity interest: 100% Sanofi Pasteur Worldwide, 2 Avenue Point, F-69367, Lyon, France

Lobbyist	Covered position, as disclosed
DONALD DALRYMPLE New	Principal

Contacted: Health & Human Services, Dept of (HHS); SENATE; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Natl Institutes of Health (NIH)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.